RedHill Biopharma announced the Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations. Scruggs is responsible for leading the Company’s U.S. commercial operations, currently promoting four GI products, and the preparations for the potential commercial launch of TALICIA (RHB-105)1 for eradication of H. pylori infection, planned for the fourth quarter of 2019. He most recently served as executive vice president of business development at Salix Pharmaceuticals Inc. until its acquisition by Valeant Pharmaceuticals International Inc.